Merck Serono buys Phase I Copaxone relative in bankruptcy sale
This article was originally published in Scrip
Executive Summary
Merck Serono has paid $1.5 million for PI-2301, a peptide copolymer that its now bankrupt former owner Peptimmune described as a "next-generation Copaxone". The asset had previously been optioned to Novartis.